Background
Acute Coronary Syndrome (ACS) remains one of the leading causes of morbidity and mortality worldwide. Approximately 40–60% of ACS patients present with multivessel coronary artery disease (MVD). Percutaneous Coronary Intervention (PCI) has become the standard revascularization strategy in ACS; however, the optimal management of non-culprit lesions remains controversial. Recent evidence suggests that complete multivessel PCI may improve long-term outcomes compared with culprit-only intervention.
Objective
This study evaluates long-term clinical outcomes associated with multivessel PCI in ACS patients, focusing on mortality, recurrent myocardial infarction, repeat revascularization, major adverse cardiovascular events (MACE), and quality of life.
Methods
A comprehensive review of randomized controlled trials, observational studies, and registry-based analyses published between 2010 and 2025 was performed. Outcomes were synthesized from major studies evaluating complete revascularization versus culprit-only PCI.
Results
Multivessel PCI demonstrated significant reductions in recurrent myocardial infarction, ischemia-driven revascularization, and major adverse cardiovascular events. Long-term survival benefits were observed in selected high-risk populations, particularly among STEMI patients undergoing staged complete revascularization.
Conclusion
Complete multivessel PCI appears to provide superior long-term cardiovascular outcomes compared with culprit-only PCI in carefully selected ACS patients. Future studies should focus on precision-guided revascularization strategies and integration of physiological assessment tools.